CytoMed Therapeutics Limited (GDTC)
USD 2.37
(-6.32%)
USD 2.37
(-6.32%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Operating Cash Flow | -3.43 Million | -1.39 Million | -1.71 Million | -849.44 Thousand | -471.84 Thousand |
| Net Income | -4.13 Million | -3.12 Million | -2.05 Million | -1.93 Million | -632.61 Thousand |
| Depreciation & Amortization | 381.14 Thousand | 392.86 Thousand | 329.87 Thousand | 292.53 Thousand | 132 Thousand |
| Deferred income taxes | - | - | - | - | - |
| Stock-based compensation | - | - | - | - | - |
| Change in working capital | 104.91 Thousand | 109.9 Thousand | -369.24 Thousand | 115.59 Thousand | -28.32 Thousand |
| Other non-cash items | -234.43 Thousand | 1.22 Million | 378.28 Thousand | 678.05 Thousand | 57.08 Thousand |
| Investing Cash Flow | -2.82 Million | -473.3 Thousand | -823.66 Thousand | -513.05 Thousand | -872.97 Thousand |
| Investments in PPE | -58.29 Thousand | -473.79 Thousand | -582.35 Thousand | -265.15 Thousand | -872.97 Thousand |
| Acquisitions | - | - | -241.31 Thousand | - | - |
| Investment purchases | -2.77 Million | - | - | -247.89 Thousand | - |
| Sales/Maturities of investments | - | - | - | - | - |
| Other Investing Activities | -2.77 Million | 490.00 | -241.31 Thousand | -268.32 Thousand | - |
| Financing Cash Flow | 10.91 Million | 968.71 Thousand | 4.17 Million | 1.88 Million | 887.24 Thousand |
| Debt repayment | -340.42 Thousand | -428.75 Thousand | -58.9 Thousand | -10.95 Thousand | -21.98 Thousand |
| Dividends payments | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - |
| Common Stock Issuance | 11.3 Million | 1.22 Million | 2 Million | 500 Thousand | - |
| Other Financing Activities | 10.96 Million | 174.82 Thousand | 2.23 Million | 1.39 Million | 909.22 Thousand |
| Accounts receivables | -5259.00 | -145.16 Thousand | -433.11 Thousand | -162.05 Thousand | 7124.27 |
| Accounts payables | - | - | - | - | - |
| Inventory | - | - | - | - | -35.44 Thousand |
| Other working capital | 110.17 Thousand | 255.07 Thousand | 63.86 Thousand | 277.64 Thousand | - |
| Cash at beginning of period | 1.57 Million | 2.51 Million | 885.27 Thousand | 370.94 Thousand | 986.82 Thousand |
| Cash at end of period | 6.22 Million | 1.57 Million | 2.51 Million | 885.27 Thousand | 275.82 Thousand |
| Capital Expenditure | -58.29 Thousand | -473.79 Thousand | -582.35 Thousand | -265.15 Thousand | -872.97 Thousand |
| Effect of forex changes on cash | -13.41 Thousand | -30.05 Thousand | -9249.00 | -6695.00 | -379.23 |
| Net cash flow / Change in cash | 4.64 Million | -933.05 Thousand | 1.62 Million | 514.33 Thousand | -711 Thousand |
| Free Cash Flow | -3.49 Million | -1.87 Million | -2.29 Million | -1.11 Million | -1.34 Million |
| Breakdown | 2024 Q2 | 2023 Q4 | 2023 FY | 2023 Q3 | 2023 Q2 | 2023 Q1 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | -807.96 Thousand | -748.21 Thousand | -4.13 Million | -722.26 Thousand | -1.61 Million | -810.81 Thousand |
| Depreciation & Amortization | 123.87 Thousand | 66.63 Thousand | 381.14 Thousand | 64.32 Thousand | 151.97 Thousand | 76.3 Thousand |
| Deferred income taxes | - | - | - | - | - | - |
| Stock-based compensation | - | - | - | - | - | - |
| Change in working capital | -127.15 Thousand | 42.3 Thousand | 104.91 Thousand | 40.83 Thousand | -197.86 Thousand | -43.92 Thousand |
| Other non-cash items | -54.08 Thousand | 109.17 Thousand | -234.43 Thousand | 105.38 Thousand | 610.3 Thousand | 14.36 Thousand |
| Investing Cash Flow | -1.4 Million | -1.06 Million | -2.82 Million | -1.02 Million | -12.81 Thousand | -6435.13 |
| Investments in PPE | -429.91 Thousand | -15.59 Thousand | -58.29 Thousand | -15.05 Thousand | -12.81 Thousand | -6435.13 |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | -354.59 Thousand | - | -2.77 Million | - | - | - |
| Sales/Maturities of investments | - | - | - | - | - | - |
| Other Investing Activities | -616.86 Thousand | -1.04 Million | -2.77 Million | -1.01 Million | - | - |
| Financing Cash Flow | -14.65 Thousand | -194.75 | 10.91 Million | -187.99 | 8.2 Million | 4.1 Million |
| Debt repayment | -11.86 Thousand | -8903.63 | -340.42 Thousand | - | -255.57 Thousand | - |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | - | -85.05 Thousand | 11.3 Million | - | 8.46 Million | - |
| Other Financing Activities | -2790.45 | -194.75 | 10.96 Million | -187.99 | 4.03 Million | 4.1 Million |
| Accounts receivables | 30.68 Thousand | 42.3 Thousand | -5259.00 | 40.83 Thousand | -87.48 Thousand | -43.92 Thousand |
| Accounts payables | -157.84 Thousand | 191.99 Thousand | - | - | -110.38 Thousand | - |
| Inventory | - | - | - | - | - | - |
| Other working capital | - | - | - | - | - | - |
| Cash at beginning of period | 6.81 Million | 7.71 Million | 1.57 Million | - | 1.17 Million | -0.73 |
| Cash at end of period | 4.42 Million | 6.81 Million | 6.22 Million | -1.54 Million | 7.71 Million | 3.32 Million |
| Capital Expenditure | -429.91 Thousand | -15.59 Thousand | -58.29 Thousand | -15.05 Thousand | -12.81 Thousand | -6435.13 |
| Effect of forex changes on cash | - | -725.94 | -13.41 Thousand | -700.76 | -4250.35 | -4319.14 |
| Net cash flow / Change in cash | -2.39 Million | -893.46 Thousand | 4.64 Million | -1.54 Million | 6.53 Million | 3.32 Million |
| Free Cash Flow | -1.29 Million | -545.7 Thousand | -3.49 Million | -526.77 Thousand | -1.56 Million | -770.51 Thousand |
CPSS
NAM
AX
2063
MORE
SVNLY